The overall purpose of the Animal Models Core (Core D) is to facilitate the accomplishment of the translational research goals and objectives of the SPORE by providing investigators with assistance in the design and generation of transgenic and knockout/knockin mouse strains, a centralized repository for these mouse strains, and material of common interest, such as dissected tissues, DNA, RNA, or protein extracts from these mouse strains.
The specific aims of the Animal Models Core are to: 1. Generate and provide transgenic and knockout/knockin mouse strains as needed by SPORE investigators. 2. Serve as a centralized repository and breeding service for mouse strains used by SPORE investigators. 3. Provide SPORE laboratories with dissected tissues, DNA, RNA, and proteins from the mouse mutants utilized by the investigators. With the recent establishment of a standardized preclinical trial protocol developed by our Core and based on phase II and III patient clinical trials, we anticipate further increased use of our Core by members of our SPORE.

Public Health Relevance

The Animal Models Core is an essential component of our SPORE in Prostate Cancer because it facilitates the timely conduct of research by centralizing services designed to prioritize the needs of our SPORE investigators: maintaining colonies of mice ready for use in preclinical studies and procuring and banking tissue from these mice for characterization of molecular markers and for RNA, DNA, and protein studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092629-14
Application #
8730093
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
City
New York
State
NY
Country
United States
Zip Code
10065
Puca, Loredana; Bareja, Rohan; Prandi, Davide et al. (2018) Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun 9:2404
Currall, Benjamin B; Chen, Ming; Sallari, Richard C et al. (2018) Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet 27:4194-4203
Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651
Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Audenet, François; Vertosick, Emily A; Fine, Samson W et al. (2018) Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. J Urol 199:961-968
Hugosson, Jonas; Godtman, Rebecka Arnsrud; Carlsson, Sigrid V et al. (2018) Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 52:27-37
Kohestani, Kimia; Chilov, Marina; Carlsson, Sigrid V (2018) Prostate cancer screening-when to start and how to screen? Transl Androl Urol 7:34-45
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Kim, Kwanghee; Watson, Philip A; Lebdai, Souhil et al. (2018) Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. Clin Cancer Res 24:2408-2416

Showing the most recent 10 out of 505 publications